免疫检查点抑制剂相关毒性的机制及其治疗的研究进展

The progress on the mechanism and treatment of immunocheckpoint inhibitors related adverse effects

免疫检查点抑制剂在肿瘤治疗中的地位日益突出,显著延长肿瘤患者的生存时间。其关键机制是特异性结合PD-1/PD-L1或CTLA-4靶点,破坏肿瘤免疫耐受,激活淋巴细胞和免疫细胞从而杀灭肿瘤细胞。然而,免疫检查点抑制剂相关毒性的机制还尚未完全明了,故了解其机制并早诊断和早治疗仍是降低毒副反应发生的重要措施。本文对免疫检查点抑制剂相关毒性的机制和治疗的研究进展进行综述。

Immunocheckpoint inhibitors are playing an increasingly prominent role in tumor therapy,significantly extending the survival time of tumor patients.The key mechanism is specific binding of PD-1/PD-L1 or CTLA-4 targets to destroy tumor immune tolerance and activate lymphocytes and immune cells to kill tumor cells.However,the intrinsic mechanism of the toxicity associated with immunocheckpoint inhibitors has not been fully understood,so understanding the intrinsic mechanism and early diagnosis and treatment are still important measures to reduce the occurrence of toxic and side effects.This paper reviews the mechanism and treatment of immunocheckpoint suppressant-related toxicity.